7 września 2026 —
An AI-designed drug produces an early biological-aging signal
Today's Daily Brief separates early evidence from finished outcomes. An AI-designed drug produced a provocative biomarker result, OpenAI's chief scientist set out a case for enforceable scaling limits, and investigations exposed difficult questions around chip controls and creator compensation. Each item links to the reporting or primary material behind it.
An AI-designed drug produces an early biological-aging signal
A new analysis of Insilico Medicine's Phase IIa trial found that rentosertib lowered estimated biological age across six proteomic aging clocks after 12 weeks. The analysis covered 42 patients with idiopathic pulmonary fibrosis, the disease the drug was designed to treat.
The result is preliminary: aging clocks are indirect biomarkers, the study was not a longevity trial, and the drug has not been tested for anti-aging effects in healthy people. It remains evidence to investigate, not proof that an AI-designed therapy slows human aging.
OpenAI's chief scientist says safety must constrain further scaling
OpenAI chief scientist Jakub Pachocki argued that no laboratory has solved alignment and monitoring well enough to scale frontier systems indefinitely without limits.
He said further scaling should be withheld when necessary and called for common safety thresholds enforced through auditors, governments or international bodies. He also warned that monitoring model reasoning may become less dependable as systems grow more capable.
A reported Inspur network exposes gaps in U.S. AI-chip controls
A New York Times investigation found that Inspur continued accessing advanced American computing technology after its 2023 Entity List designation through a network that included its Silicon Valley subsidiary Aivres and intermediaries in Southeast Asia.
The reporting draws on shipment records, contracts, corporate documents, site visits and interviews. It illustrates how corporate structure and resale channels can make hardware restrictions harder to enforce than a blacklist alone suggests.
Authors challenge competing claims on Anthropic settlement payments
Authors covered by Anthropic's $1.5 billion copyright settlement are receiving notices that publishers or literary agents have asserted competing claims on their payments.
The approved settlement generally allocates $3,000 per covered work, while publisher splits depend on the underlying rights. Writers and advocacy groups say some claims involve reverted rights or exceed contractual shares; publishers have attributed some disputes to record errors.
Pixxel raises $100 million to expand its Earth-intelligence stack
Los Angeles- and Bengaluru-based Pixxel closed a $100 million Series C co-led by Temasek and Seraphim Space, taking its reported total funding to $195 million.
The company plans to expand its sensing constellation, add high-resolution optical satellites, increase manufacturing capacity and develop Aurora, software intended to turn multi-sensor imagery into decision-ready intelligence.
OpenAI backs AI projects in ten Ukrainian newsrooms
OpenAI, WAN-IFRA and AIRPPU announced training, project support and API credits for ten independent Ukrainian publishers.
The program covers editorial, audience, product, revenue and operational workflows, giving the participating newsrooms support to test specific uses rather than adopting a generic AI mandate.
UBS makes AI fluency part of junior-bank hiring
UBS is asking graduate and intern candidates for its global banking and markets business to explain how they have used AI to improve outcomes and efficiency.
The requirement adds practical AI fluency to conventional academic and interview criteria, but it does not establish a single tool or workflow that every applicant must use.
Anthropic's Labs team runs product bets on two-week cycles
Anthropic cofounder Ben Mann says the roughly 20-person Labs group reviews experimental product bets every two weeks and graduates promising projects into standalone teams.
Claude Code and the Model Context Protocol emerged from the incubator, making the team a useful case study in how an AI company separates rapid product experiments from its larger organization.